Novo Nordisk is well-positioned in the obesity drug market, with strong financials and anticipation for its oral Wegovy pill.

HRT May Get Revised Label; Costco to Sell No-Insurance Ozempic; CGM Without Diabetes The FDA is considering changing the ...

A federal appeals court on Monday rejected Novo Nordisk's challenge to the U.S. government’s program that gives its Medicare ...

Mass General Brigham researchers found that continuous glucose monitoring metrics were reflective of a common measure of glucose (hemoglobin A1c) in patients with diabetes, but fell short for people w ...

Because of its size, the drugmaker has an outsize effect on the country. Now, as it sheds jobs, forecasts for Denmark’s growth are falling, too. By Eshe Nelson The success of Novo Nordisk, the ...

Novo Nordisk has recently encountered headwinds in its core therapeutic area. The company has implemented changes that could pay off in the long run. Novo Nordisk's shares look reasonably valued. 10 ...

Two years ago, Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company, was performing so well that it was positively affecting the economy of its home country. However, the past 18 months ...

In a new study, Ozempic-maker Novo Nordisk shows that its weight loss pill could achieve the similar efficacy as injectables. Novo Nordisk's Chief Scientific Officer says they're expecting FDA ...

Berenberg Bank just upgraded Novo Nordisk to a buy. The banker believes investor expectations have reset and it's now possible Novo Nordisk has fallen enough to bounce again. Novo Nordisk created the ...

Novo Nordisk (NYSE: NVO)-- the original Ozempic stock-- is getting a boost from a Financial Times report this morning highlighting positive results from two weight loss trials using increased dosages ...

Novo Nordisk (NASDAQ Copenhagen: NOVO-B) inflicted much pain—and much-needed pain—on the company when president and CEO Maziar (Mike) Doustdar announced plans to lay off about 9,000 of its 78,400 ...